Rethinking the benefits of digital adherence technologies for tuberculosis treatment

Affiliations

¹ Department of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany; South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa. Electronic address: florian.marx@uni-heidelberg.de.
² Department of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Comment

Florian M Marx et al. Lancet. 2025.

. 2025 Apr 5;405(10485):1122-1123.

doi: 10.1016/S0140-6736(25)00199-0. Epub 2025 Mar 11.

¹ Department of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany; South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa. Electronic address: florian.marx@uni-heidelberg.de.
² Department of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.

No abstract available

Conflict of interest statement

We declare no competing interests.

Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials.
Jerene D, van Kalmthout K, Levy J, Alacapa J, Deyanova N, Dube T, Mganga A, Tasca B, Bogdanov A, Efo E, Gamazina K, Garfin AMC, Kochanov V, Leung A, Madden N, Maraba N, McQuaid CF, Mleoh L, Onjare B, Powers R, Terleiva Y, van Rest J, Gebhard A, Fielding K, Charalambous S. Jerene D, et al. Lancet. 2025 Apr 5;405(10485):1155-1166. doi: 10.1016/S0140-6736(24)02847-2. Epub 2025 Mar 11. Lancet. 2025. PMID: 40086457 Clinical Trial.